{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:52Z","timestamp":1786991272784,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017357","name":"Science and Technology Projects of Fujian Province","doi-asserted-by":"publisher","award":["2023Y9025"],"award-info":[{"award-number":["2023Y9025"]}],"id":[{"id":"10.13039\/100017357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["2023QH1296"],"award-info":[{"award-number":["2023QH1296"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010849","name":"Wuhan Municipal Health Commission","doi-asserted-by":"publisher","award":["WZ21C30"],"award-info":[{"award-number":["WZ21C30"]}],"id":[{"id":"10.13039\/501100010849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jad.2025.120158","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:17:39Z","timestamp":1756221459000},"page":"120158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder"],"prefix":"10.1016","volume":"392","author":[{"given":"Jianmin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudie","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120158_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2025.120158_bb0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jad.2021.02.027","article-title":"Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder","volume":"285","author":"Arnaud","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120158_bb0015","article-title":"Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor","volume":"12","author":"Belelli","year":"2019","journal-title":"Neurobiol. Stress"},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/psp4.12041","article-title":"The many flavors of model-based meta-analysis: part I-introduction and landmark data","volume":"5","author":"Boucher","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"5","key":"10.1016\/j.jad.2025.120158_bb0030","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/psp4.12299","article-title":"Many flavors of model-based meta-analysis: part II - modeling summary level longitudinal responses","volume":"7","author":"Boucher","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ijnp\/pyz062","article-title":"Analysis of time-course, dose-effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression","volume":"23","author":"Cheng","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10128","key":"10.1016\/j.jad.2025.120158_bb0040","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0045","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14445","article-title":"Zuranolone in major depressive disorder: results from MOUNTAIN-A phase 3, multicenter, double-blind, randomized, placebo-controlled trial","volume":"84","author":"Clayton","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2025.120158_bb0050","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/appi.ajp.20220459","article-title":"Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 trial","volume":"180","author":"Clayton","year":"2023","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.120158_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.jad.2025.120158_bb0060","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","article-title":"Overview of model-building strategies in population PK\/PD analyses: 2002-2004 literature survey","volume":"64","author":"Dartois","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jad.2025.120158_bb0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling","volume":"43","author":"Dosne","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"12","key":"10.1016\/j.jad.2025.120158_bb0070","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamapsychiatry.2019.2859","article-title":"Association of antidepressant use with adverse health outcomes: a systematic umbrella review","volume":"76","author":"Dragioti","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2025.120158_bb0075","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.120158_bb0080","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","year":"2021"},{"issue":"1","key":"10.1016\/j.jad.2025.120158_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, a novel GABA(A) receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.jad.2025.120158_bb0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/pcn.13569","article-title":"Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: a double-blind, randomized, placebo-controlled, phase 2 clinical trial","volume":"77","author":"Kato","year":"2023","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.120158_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0100","first-page":"173","article-title":"Pharmacologic treatment of depression","volume":"107","author":"Kovich","year":"2023","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.jad.2025.120158_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115640","article-title":"Efficacy and safety of zuranolone for the treatment of depression: a systematic review and meta-analysis","volume":"331","author":"Li","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.120158_bb0110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jad.2024.03.057","article-title":"Different dosage regimens of zuranolone in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials","volume":"354","author":"Lian","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120158_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102308","article-title":"Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses","volume":"66","author":"Lin","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.jad.2025.120158_bb0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/mp.2010.120","article-title":"The GABAergic deficit hypothesis of major depressive disorder","volume":"16","author":"Luscher","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"10161","key":"10.1016\/j.jad.2025.120158_bb0125","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.jad.2025.120158_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-023-00454-1","article-title":"Major depressive disorder","volume":"9","author":"Marx","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.jad.2025.120158_bb0135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/acschemneuro.0c00467","article-title":"Classics in chemical neuroscience: amitriptyline","volume":"12","author":"McClure","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.jad.2025.120158_bb0140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1358\/dof.2019.44.6.2958473","article-title":"Zuranolone GABAA receptor positive allosteric modulator, treatment of major depressive disorder, treatment of postpartum depression","volume":"44","author":"Mehta","year":"2019","journal-title":"Drugs Future"},{"key":"10.1016\/j.jad.2025.120158_bb0145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jad.2023.08.027","article-title":"Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder","volume":"340","author":"Meshkat","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"10","key":"10.1016\/j.jad.2025.120158_bb0150","first-page":"774","article-title":"FDA approves first oral drug for postpartum depression, but rejects it for major depressive disorder","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0160","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41386-023-01751-9","article-title":"Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study","volume":"49","author":"Parikh","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jad.2025.120158_bb0165","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/JCP.0b013e31817efbac","article-title":"Physician Withdrawal Checklist (PWC-20)","volume":"28","author":"Rickels","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.jad.2025.120158_bb0170","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ps.201900625","article-title":"Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States","volume":"71","author":"Ross","year":"2020","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.jad.2025.120158_bb0175","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1017\/S1092852923002092","article-title":"Zuranolone, a positive allosteric modulator of the GABAA receptor: hypothesized mechanism of action in major depressive disorder","volume":"28","author":"Stahl","year":"2023","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.jad.2025.120158_bb0180","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cpt.1462","article-title":"Model-based meta-analysis: optimizing research, development, and utilization of therapeutics using the totality of evidence","volume":"106","author":"Upreti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jad.2025.120158_bb0185","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jcph.668","article-title":"Short-term efficacy reliably predicts long-term clinical benefit in rheumatoid arthritis clinical trials as demonstrated by model-based Meta-analysis","volume":"56","author":"Wang","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.120158_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115503","article-title":"Applications of pharmacometrics in drug development","volume":"217","author":"Xiong","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.jad.2025.120158_bb0195","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/CM9.0000000000003138","article-title":"Efficacy and dose-response relationships of antidepressants in the acute treatment of major depressive disorders: a systematic review and network meta-analysis","volume":"138","author":"Zhou","year":"2025","journal-title":"Chin. Med. J."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725016003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725016003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:12:10Z","timestamp":1780204330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725016003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S0165032725016003"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120158","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120158"}}